Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022

-TQS-168 demonstrated robust geroprotective effects in preclinical studies- REDWOOD CITY, Calif.–(BUSINESS WIRE)–Tranquis Therapeutics, Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced it will present preclinical data on the anti-aging effects of TQS-168, a small molecule modulator of PGC-1a, at ARDD … [Read more…]

Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

-Treatment with Cemdisiran Resulted in a Higher Proportion of Patients Achieving Clinically Meaningful Reductions in 24-Hour Urine Protein to Creatinine Ratio, as Compared to Patients on Placebo – – Consistent Proteinuria Reduction Seen with Secondary Endpoints – – Cemdisiran Was Generally Well-Tolerated in Patients with IgA Nephropathy – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) … [Read more…]

Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals

PEARL RIVER, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a license agreement relating to its preclinical asset, Nepicastat, with Asieris Pharmaceuticals, a biotechnology company headquartered in China. Under the terms of the agreement, Acorda will receive an upfront payment of $500,000, and up to an additional $7 million based … [Read more…]

Levine Leichtman Capital Partners Sells Monte Nido

LOS ANGELES–(BUSINESS WIRE)–Levine Leichtman Capital Partners (“LLCP”), a Los Angeles-based private equity firm, announced today that it has sold its portfolio company Monte Nido & Affiliates (“Monte Nido” or the “Company”) to funds managed by Revelstoke Capital Partners LLC. Financial terms of the transaction were not disclosed. Founded in 1996, Monte Nido is a leading … [Read more…]

Catalent, Inc. Reports Fourth Quarter Fiscal 2022 Results

Q4’22 net revenue of $1.31 billion increased 10% as reported, or 15% in constant currency, compared to Q4’21. Organic, constant-currency net revenue grew 10%, compared to Q4’21. Fiscal 2022 net revenue of $4.83 billion increased 21% as reported, or 23% in constant currency, compared to fiscal 2021. Organic, constant-currency net revenue grew 20% compared to … [Read more…]

ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP

BAUDETTE, Minn.–(BUSINESS WIRE)–ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg. ANI’s Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg are the generic version of the Reference Listed Drug (RLD) Compazine® and were developed in technical collaboration with Biophore India … [Read more…]

Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer

Longer-term survival results underscoring role of KEYTRUDA® (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189) Seven-year survival from SOLO-1 and final overall survival (OS) results from PAOLA-1 highlight role of LYNPARZA® (olaparib) in first-line maintenance of advanced ovarian cancer First presentation of KEYTRUDA in combination with an antibody-drug conjugate (enfortumab … [Read more…]

Bruker Launches New nanoElute® 2 nano-LC For 4D-Proteomics, Advances Fluxomics Applications with MetaboScape® 2023 Software

New nanoElute 2 features nano-LC advances, supports automated single cell sample preparation from label-free ProteoCHIP on CellenONE platform MetaboScape® 2023 advances fluxomics applications and ion mobility offset mass aligned (‘MOMA’) events for high-throughput 4D-Metabolomics Advances in MALDI HiPLEX-IHC™ workflows, and in PaSER™ on-the-fly intelligent acquisition software for 4D-Metaproteomics MAASTRICHT, Netherlands–(BUSINESS WIRE)–$BRKR #BRKR–At the International Mass … [Read more…]

Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–$EOLS–Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the H.C. Wainwright 24th Annual Global Investment Conference. Event: H.C. Wainwright 24th Annual Global Investment Conference Date: Monday, September 12, 2022 Time: Available … [Read more…]

Revitalist Updates Infrastructure for Aggressive Growth Strategy in 2022

VANCOUVER, British Columbia–(BUSINESS WIRE)–#education–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO), a Veteran and Nurse lead ketamine wellness company, is pleased to report updated company structures aligning the mission of the company for aggressive strategic growth opportunities in the psychedelic wellness field. Revitalist CEO, Kathryn Walker states, “Revitalist … [Read more…]